Cargando…

Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER

BACKGROUND: This study aimed to examine the impact of baseline eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio on clinical outcomes of patients with acute coronary syndrome. METHODS AND RESULTS: In the HIJ‐PROPER (Heart Institute of Japan Proper Level of Lipid Lowering With Pitavastatin a...

Descripción completa

Detalles Bibliográficos
Autores principales: Arashi, Hiroyuki, Yamaguchi, Junichi, Kawada‐Watanabe, Erisa, Koyanagi, Ryo, Sekiguchi, Haruki, Mori, Fumiaki, Haruta, Shoji, Ishii, Yasuhiro, Murasaki, Satoshi, Suzuki, Kazuhito, Yamauchi, Takao, Ogawa, Hiroshi, Hagiwara, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759903/
https://www.ncbi.nlm.nih.gov/pubmed/31390907
http://dx.doi.org/10.1161/JAHA.119.012953
_version_ 1783453782350233600
author Arashi, Hiroyuki
Yamaguchi, Junichi
Kawada‐Watanabe, Erisa
Koyanagi, Ryo
Sekiguchi, Haruki
Mori, Fumiaki
Haruta, Shoji
Ishii, Yasuhiro
Murasaki, Satoshi
Suzuki, Kazuhito
Yamauchi, Takao
Ogawa, Hiroshi
Hagiwara, Nobuhisa
author_facet Arashi, Hiroyuki
Yamaguchi, Junichi
Kawada‐Watanabe, Erisa
Koyanagi, Ryo
Sekiguchi, Haruki
Mori, Fumiaki
Haruta, Shoji
Ishii, Yasuhiro
Murasaki, Satoshi
Suzuki, Kazuhito
Yamauchi, Takao
Ogawa, Hiroshi
Hagiwara, Nobuhisa
author_sort Arashi, Hiroyuki
collection PubMed
description BACKGROUND: This study aimed to examine the impact of baseline eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio on clinical outcomes of patients with acute coronary syndrome. METHODS AND RESULTS: In the HIJ‐PROPER (Heart Institute of Japan Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome) study, 1734 patients with acute coronary syndrome and dyslipidemia were randomly assigned to pitavastatin+ezetimibe therapy or pitavastatin monotherapy. We divided the patients into 2 groups based on EPA/AA ratio on admission (cutoff 0.34 μg/mL as median of baseline EPA/AA ratio) and examined their clinical outcomes. The primary end point comprised all‐cause death, nonfatal myocardial infarction, nonfatal stroke, unstable angina pectoris, or ischemia‐driven revascularization. Percentage reduction of low‐density lipoprotein cholesterol and triglyceride from baseline to follow‐up was similar regardless of baseline EPA/AA ratio. Despite the mean low‐density lipoprotein cholesterol level during follow‐up being similar between the low‐ and high‐EPA/AA groups, the mean triglyceride levels during follow‐up were significantly higher in the low‐ than in the high‐EPA/AA group. After 3 years of follow‐up, the cumulative incidence of the primary end point in patients with low EPA/AA was 27.2% in the pitavastatin+ezetimibe group compared with 36.6% in the pitavastatin‐monotherapy group (hazard ratio 0.69; 95% CI, 0.52‐0.93; P=0.015). However, there was no effect of pitavastatin+ezetimibe therapy on the primary end point in patients with high EPA/AA (hazard ratio 0.92; 95% CI, 0.70‐1.20; P=0.52). CONCLUSIONS: Among acute coronary syndrome patients who have dyslipidemia and low EPA/AA ratio, adding ezetimibe to statin decreases the risk of cardiovascular events compared with statin monotherapy. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr. Unique identifier: UMIN000002742
format Online
Article
Text
id pubmed-6759903
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67599032019-09-30 Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER Arashi, Hiroyuki Yamaguchi, Junichi Kawada‐Watanabe, Erisa Koyanagi, Ryo Sekiguchi, Haruki Mori, Fumiaki Haruta, Shoji Ishii, Yasuhiro Murasaki, Satoshi Suzuki, Kazuhito Yamauchi, Takao Ogawa, Hiroshi Hagiwara, Nobuhisa J Am Heart Assoc Original Research BACKGROUND: This study aimed to examine the impact of baseline eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio on clinical outcomes of patients with acute coronary syndrome. METHODS AND RESULTS: In the HIJ‐PROPER (Heart Institute of Japan Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome) study, 1734 patients with acute coronary syndrome and dyslipidemia were randomly assigned to pitavastatin+ezetimibe therapy or pitavastatin monotherapy. We divided the patients into 2 groups based on EPA/AA ratio on admission (cutoff 0.34 μg/mL as median of baseline EPA/AA ratio) and examined their clinical outcomes. The primary end point comprised all‐cause death, nonfatal myocardial infarction, nonfatal stroke, unstable angina pectoris, or ischemia‐driven revascularization. Percentage reduction of low‐density lipoprotein cholesterol and triglyceride from baseline to follow‐up was similar regardless of baseline EPA/AA ratio. Despite the mean low‐density lipoprotein cholesterol level during follow‐up being similar between the low‐ and high‐EPA/AA groups, the mean triglyceride levels during follow‐up were significantly higher in the low‐ than in the high‐EPA/AA group. After 3 years of follow‐up, the cumulative incidence of the primary end point in patients with low EPA/AA was 27.2% in the pitavastatin+ezetimibe group compared with 36.6% in the pitavastatin‐monotherapy group (hazard ratio 0.69; 95% CI, 0.52‐0.93; P=0.015). However, there was no effect of pitavastatin+ezetimibe therapy on the primary end point in patients with high EPA/AA (hazard ratio 0.92; 95% CI, 0.70‐1.20; P=0.52). CONCLUSIONS: Among acute coronary syndrome patients who have dyslipidemia and low EPA/AA ratio, adding ezetimibe to statin decreases the risk of cardiovascular events compared with statin monotherapy. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr. Unique identifier: UMIN000002742 John Wiley and Sons Inc. 2019-08-08 /pmc/articles/PMC6759903/ /pubmed/31390907 http://dx.doi.org/10.1161/JAHA.119.012953 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Arashi, Hiroyuki
Yamaguchi, Junichi
Kawada‐Watanabe, Erisa
Koyanagi, Ryo
Sekiguchi, Haruki
Mori, Fumiaki
Haruta, Shoji
Ishii, Yasuhiro
Murasaki, Satoshi
Suzuki, Kazuhito
Yamauchi, Takao
Ogawa, Hiroshi
Hagiwara, Nobuhisa
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
title Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
title_full Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
title_fullStr Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
title_full_unstemmed Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
title_short Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
title_sort polyunsaturated fatty acid impact on clinical outcomes in acute coronary syndrome patients with dyslipidemia: subanalysis of hij‐proper
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759903/
https://www.ncbi.nlm.nih.gov/pubmed/31390907
http://dx.doi.org/10.1161/JAHA.119.012953
work_keys_str_mv AT arashihiroyuki polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT yamaguchijunichi polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT kawadawatanabeerisa polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT koyanagiryo polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT sekiguchiharuki polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT morifumiaki polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT harutashoji polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT ishiiyasuhiro polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT murasakisatoshi polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT suzukikazuhito polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT yamauchitakao polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT ogawahiroshi polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper
AT hagiwaranobuhisa polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper